AcouSort sells AcouWash system to Japanese distributor
AcouSort has sold an AcouWash system to its Japanese distributor Physio-Tech. Physio-Tech has over the last year worked intensively with introducing AcouSort’s bench-top systems to the Japanese market. Since the purchase of the AcouTrap system early 2021, the interest for AcouSort’s systems has grown significantly and Physio-Tech has now purchased an AcouWash system to meet the increased demand.
During the spring, AcouSort's distributor on the Japanese market has intensified the marketing of AcouSort's systems to Japanese companies and research groups. The effort has been very successful and there are several customers that are interested in a demo of the AcouWash system as soon as the Covid-19 situation allows.
“The efforts made by Physio-Tech to establish contacts with Japanese research groups and life science companies has continued with undiminished strength during spring 2021. We now look forward to having both the AcouWash and the AcouTrap system in place at Physio-Tech so that the commercialization of our bench-top systems can continue in an efficient way,” says AcouSort’s CEO Torsten Freltoft.
Since 1980, Physio-Tech is a well-established distributor specializing in import, development, and sales of medical research equipment. An increased exposure of AcouSort's products and technology on the Japanese market is also expected to stimulate interest in OEM collaborations from Japanese life science companies.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.